Wall Street brokerages predict that argenx SE – (NASDAQ:ARGX) will report earnings per share (EPS) of ($0.59) for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for argenx’s earnings, with estimates ranging from ($0.72) to ($0.52). The company is scheduled to issue its next earnings results before the market opens on Thursday, August 2nd.
According to Zacks, analysts expect that argenx will report full year earnings of ($2.62) per share for the current year, with EPS estimates ranging from ($2.90) to ($2.38). For the next year, analysts expect that the company will post earnings of ($3.61) per share, with EPS estimates ranging from ($4.16) to ($3.20). Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow argenx.
Get argenx alerts:A number of equities research analysts have issued reports on ARGX shares. Cowen reaffirmed a “buy” rating on shares of argenx in a research report on Wednesday, June 6th. Wedbush reaffirmed an “outperform” rating and set a $92.00 target price (down previously from $93.00) on shares of argenx in a research report on Thursday, May 10th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $130.00 target price on shares of argenx in a research report on Thursday, June 7th. JMP Securities upped their target price on argenx from $93.00 to $130.00 and gave the stock a “positive” rating in a research report on Monday, June 18th. Finally, SunTrust Banks started coverage on argenx in a research report on Sunday, April 8th. They set a “buy” rating and a $125.00 target price for the company. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. argenx presently has a consensus rating of “Buy” and a consensus target price of $122.83.
A number of institutional investors have recently made changes to their positions in ARGX. Aperio Group LLC bought a new stake in argenx during the first quarter worth approximately $268,000. US Bancorp DE bought a new stake in argenx during the first quarter worth approximately $598,000. BB Biotech AG bought a new stake in argenx during the first quarter worth approximately $31,920,000. Northern Trust Corp bought a new stake in shares of argenx in the first quarter valued at approximately $896,000. Finally, Dimensional Fund Advisors LP bought a new stake in shares of argenx in the first quarter valued at approximately $498,000. 53.14% of the stock is owned by hedge funds and other institutional investors.
argenx traded down $0.20, reaching $91.93, during trading hours on Thursday, MarketBeat.com reports. 72,300 shares of the company were exchanged, compared to its average volume of 145,418. The stock has a market capitalization of $2.92 billion, a P/E ratio of -65.66 and a beta of 2.44. argenx has a 12 month low of $19.81 and a 12 month high of $103.00.
About argenx
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Featured Story: Closed-End Mutual Funds
Get a free copy of the Zacks research report on argenx (ARGX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment